Synthesis of the pyrazolo[3,4‐d]pyrimidin‐3‐one congeners of guanosine, adenosine and inosine is described. Glycosylation of 3‐methoxy‐6‐methylthio‐1H‐pyrazolo[3,4‐d]pyrimidin‐4(5H)‐one (13) with 1‐O‐acetyl‐2,3,5‐tri‐O‐benzoyl‐D‐ribofuranose (16) in the presence of boron trifluoride etherate gave 3‐methoxy‐6‐methylthio‐1‐(2,3,5‐tri‐O‐benzoyl‐β‐D‐ribofuranosyl)pyrazolo[3,4‐d]pyrimidin‐4(5H)‐one (17) which, after successive treatments with 3‐chloroperoxybenzoic acid and methanolic ammonia, afforded 6‐amino‐3‐methoxy‐1‐β‐D‐ribofuranosylpyrazolo[3,4‐d]pyrimidin‐4(5H)one (18). The guanosine analog, 6‐amino‐1‐β‐D‐ribofuranosylpyrazolo[3,4‐d]pyrimidine‐3,4(2H,5H)‐dione (21), was made by sodium iodide‐chlorotrimethylsilane treatment of 6‐amino‐3‐methoxy‐1‐(2,3,5‐tri‐O‐acetyl‐β‐D‐ribofuranosyl)pyrazolo[3,4‐d]pyrimidin‐4(5H)one (19), followed by sugar deprotection. Treatment of the adenine analog, 4‐amino‐1H‐pyrazolo[3,4‐d]pyrimidin‐3(2H)‐one (11), according to the high temperature glycosylation procedure yielded a mixture of N‐1 and N‐2 ribosyl‐attached isomers. Deprotection of the individual isomers afforded 4‐amino‐3‐hydroxy‐1‐βribofuranosylpyrazolo‐[3,4‐d]pyrimidine (26) and 4‐amino‐2‐β‐D‐ribofuranosylpyrazolo[3,4‐d]pyrimidin‐3(7H)‐one (27). The structures of 26 and 27 were established by single crystal X‐ray diffraction analysis. The inosine analog, 1‐β‐D‐ribofuranosylpyrazolo[3,4‐d]pyrimidine‐3,4(2H,5H)‐dione (28), was synthesized enzymatically by direct ribosylation of 1H‐pyrazolo[3,4‐d]pyrimidine‐3,4(2H,5H)‐dione (8) with ribose‐1‐phosphate in the presence of purine nucleoside phosphorylase, and also by deamination of 26 with adenosine deaminase.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (1990) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: